Conduit Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
A group of investment entities led by Ascent Partners and Eagle Claw Corp. has reported a 9.9% beneficial ownership stake in CDT Equity Inc. following an internal management reorganization.
NASDAQ
Nirland Limited and affiliated entities filed a Schedule 13G disclosing a 1.6% beneficial ownership stake in CDT Equity Inc. common stock.
NASDAQ
Sarborg Ltd has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in CDT Equity Inc. following a recent reverse stock split.
NASDAQ
SCHEDULE 13G: Alliance Global Partners and Affiliates Disclose 9.77% Stake in Conduit Pharmaceuticals Inc.
A group including A.G.P. / Alliance Global Partners, LLC, Alliance Global Holdings, Inc., and several individuals, has disclosed a beneficial ownership of 9.77% of Conduit Pharmaceuticals Inc.'s common stock.
NASDAQ
Sarborg Ltd has filed a Schedule 13G, reporting a 16.4% passive beneficial ownership stake in Conduit Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
AstraZeneca PLC and its subsidiary AstraZeneca AB have filed an amended Schedule 13G, reporting a 1.1% passive beneficial ownership stake in Conduit Pharmaceuticals Inc.
NASDAQ
SCHEDULE 13G/A: Key Investors Report Zero Beneficial Ownership in Conduit Pharmaceuticals Inc. via Amended SEC Filing
An amended Schedule 13G filing reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited collectively report 0% beneficial ownership in Conduit Pharmaceuticals Inc.
NASDAQ
Nirland Limited and related Guernsey-based entities have disclosed a beneficial ownership of 9.979% in Conduit Pharmaceuticals Inc., stemming from the conversion of a Senior Secured Promissory Note.